Remove 2016 Remove Pharmaceutical Companies Remove White Paper
article thumbnail

Time to change the channel? The future for customer engagement models

pharmaphorum

The pandemic has triggered a change in how pharmaceutical companies are engaging with healthcare professionals. When IQVIA polled non COVID-19 treating Italian HCPs in March when the crisis was at its worst, it asked HCPs if they still welcomed pharmaceutical company engagement during the crisis. The answer was yes.

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

She has an extremely wide experience of international pharmaceutical industry issues, consulting to the world’s leading pharmaceutical companies on global issues. Launches, therefore, were happening. But were they fulfilling their commercial potential? the impact of the pandemic on medicines markets and Rx launch.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Removing Regulatory Hurdles for Continuous Pharmaceutical Manufacturing

ISPE

For example, one pharmaceutical company that switched to CM reported a 50% reduction in operating costs, a 33% reduction in waste, an 80% reduction in manufacturing and testing cycle time, and a 66% reduction in time from testing to release. In 2016, CDER approved the first switch from batch to CM for a drug product. Jayjock, N.

FDA 52
article thumbnail

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Pharmaceutical Technology

About Teddy Clinical Research Laboratory : As a joint venture company established in 2016 by Dian Diagnostics (300244.SZ) SZ) and Tigermed (300347.SZ